Aura Biosciences, Inc. (AURA)

NASDAQ: AURA · IEX Real-Time Price · USD
17.81 -0.35 (-1.93%)
Jan 21, 2022 4:00 PM EST - Market closed

Company Description

Aura Biosciences is a clinical-stage biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology.

Our proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs.

Our VDCs are largely agnostic to tumor type and can recognize a surface marker that is specifically modified and broadly expressed on many tumors. AU-011, our first VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved.

We have completed a Phase 1b/2 trial. These data supported advancement into a Phase 2 dose escalation trial. We plan to present six to twelve month safety and efficacy data from this trial in 2022, and, if favorable, initiate a pivotal trial in the second half of 2022.

We are also developing AU-011 for additional ocular oncology indications and plan to file an IND in the United States in second half of 2022 for choroidal metastases.

We also plan to initiate a Phase 1a trial in non-muscle invasive bladder cancer in the second half of 2022.

Aura Biosciences, Inc.
CountryUnited States
Founded2007
IPO DateOct 29, 2021
IndustryBiotechnology
SectorHealth Care
Employees42
CEOElisabet de los Pinos, Ph.D.

Contact Details

Address:
85 Bolton Street
Cambridge, MA 02140
United States
Phone(617) 500-8864
Websiteaurabiosciences.com

Stock Details

Ticker SymbolAURA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$14.00
CIK Code1501796

Key Executives

NamePosition
Elisabet de los Pinos, Ph.D.Chief Executive Officer and Director
Julie FederChief Financial Officer
Cadmus Rich, M.D.Chief Medical Officer and Head of Research and Development
Mark De Rosch, Ph.D.Chief Operating Officer
Christopher PrimianoChief Business Officer
David JohnsonChairman and Director
Giovanni Mariggi, Ph.D.Director
Raj Parekh, Ph.D.Director

Latest SEC Filings

DateTypeTitle
Nov 24, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 24, 20218-KCurrent report
Nov 12, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 12, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 10, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Nov 10, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 4, 20214Statement of changes in beneficial ownership of securities
Nov 4, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Nov 4, 20214Statement of changes in beneficial ownership of securities
Nov 2, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings